Working to empower an underserved patient community

While many factors can contribute to hair loss, including aging, stress or medical treatment, one of the lesser-known causes is an autoimmune disease called alopecia areata, which affects approximately 3 million people in the U.S.¹

People unfamiliar with alopecia areata may think of hair loss as just cosmetic, but this chronic disease can have an unpredictable and profound impact on a person’s life, well beyond the hair loss itself.²

Because awareness remains an unmet need, social stigmatization endures. Some individuals living with alopecia areata may face periods of bullying or feel that they need to explain their condition to others.³

Lily, a Pfizer colleague who has lived with alopecia areata since childhood, recently shared some of her experiences with the condition and shed light on the challenges this patient community faces each day.

In 2021, Pfizer is committed to educating the world about this misunderstood disease while working to advance innovative potential treatments. We look forward to sharing more late-stage data for our breakthrough oral JAK3/TEC inhibitor, ritlecitinib, which, if successful in clinical trials, could represent a significant scientific innovation for patients who currently have limited and largely cosmetic options.